Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Kenneth D. Paull"'
Autor:
Susan E. Bates, Manuel Alvarez, Tito Fojo, Robert W. Robey, Kenneth D. Paull, Yoshihito Matsumoto, K. Nishiyama, Victor Sandor
Publikováno v:
Molecular Pharmacology. 54:802-814
The MRP gene contributes to one form of multidrug resistance. To identify drugs interacting with MRP, we measured MRP mRNA expression by quantitative PCR in 60 cell lines of the National Cancer Institute Anticancer Drug Screen. Expression was detecte
Autor:
Susan E. Bates, Kenneth D. Paull, Kathryn R. Johnson, John N. Weinstein, Timothy G. Myers, Katja Wosikowski, Danita Schuurhuis
Publikováno v:
JNCI Journal of the National Cancer Institute. 89:1505-1515
Background: Growth factor receptor-signaling pathways are potentially important targets for anticancer therapy. The interaction of anticancer agents with specific molecular targets can be identified by correlating target expression patterns with cyto
Autor:
Timothy G. Myers, Tatiana Connolly, Kenneth H. Cowan, Jeffrey A. Moscow, C. C. Cheng, Kenneth D. Paull
Publikováno v:
International Journal of Cancer. 72:184-190
Methotrexate transport deficiency due to decreased reduced folate carrier (RFC) activity has been observed in several cell lines selected for resistance to methotrexate (MTX). Since MTX resistance is multifactorial, however, it is difficult to quanti
Autor:
Chii M. Lin, Hui Kang Wang, Ernest Hamel, Jacqueline Plowman, Kuo Hsiung Lee, Kenneth D. Paull
Publikováno v:
Biochemical Pharmacology. 51:53-59
A series of derivatives of 2,3-dihydro-2-(aryl)-4(1H)-quinazolinone (DHQZ) with known antitumor activity was re-evaluated in the National Cancer Institute cancer cell line screen. Analysis by the COMPARE algorithm suggested that their cytotoxicity de
Autor:
Michael R. Boyd, Kenneth D. Paull
Publikováno v:
Drug Development Research. 34:91-109
During 1985-1990 the U.S. National Cancer Institute (NCI) phased out its murine leukemia P388 anticancer drug screening program and developed as the replacement a new in vitro primary screen based upon a diverse panel of human tumor cell lines. For e
Autor:
Hiremagalur N. Jayaram, Kenneth D. Paull, Ajay Sreenath, Kamran Gharehbaghi, Karsten Krohn, Zhang Hao, David A. Cooney, Thomas Szekeres
Publikováno v:
Biochemical Pharmacology. 48:1413-1419
The biochemical and cytotoxic activities of the IMP dehydrogenase (IMPDH) inhibitors benzamide riboside, tiazofurin, and selenazofurin were compared. These three C-nucleosides exert their cytotoxicity by forming an analogue of NAD, wherein nicotinami
Autor:
Mark Cushman, John F. Barrett, Rudiger D. Haugwitz, Kenneth D. Paull, Ravi K. Varma, Jurjus Jurayj
Publikováno v:
Journal of Medicinal Chemistry. 37:2190-2197
9-Methoxy-2-methylellipticinium acetate (6), along with the 9-methyl and 9-chloro derivatives (7, and 8, respectively) have shown remarkable selectivities in vitro against the NCI human CNS cancer subpanel. In order to target these types of compounds
Autor:
Kenneth D. Paull, John N. Weinstein, Kurt W. Kohn, Antonis D. Koutsoukos, Richard M. Simon, David Faraggi, Sivaram Kalyandrug, Larry Rubinstein
Publikováno v:
Statistics in Medicine. 13:719-730
The National Cancer Institute currently tests approximately 400 compounds per week against a panel of human tumour cell lines in order to identify potential anti-cancer drugs. We describe several approaches, based on these in vitro data, to the probl
Autor:
John N. Weinstein, N. L. Anderson, K. Raghavan, Jonathan D. Licht, Dominic A. Scudiero, Timothy G. Myers, Daniel W. Zaharevitz, W. W. Van Osdol, Vellarkad N. Viswanadhan, Kenneth D. Paull, John K. Buolamwini, Larry Rubinstein, Bruce A. Chabner, Antonis D. Koutsoukos, Anne Monks, Kurt W. Kohn, Michael R. Grever
Publikováno v:
STEM CELLS. 12:13-22
The National Cancer Institute's drug discovery program screens more than 20,000 chemical compounds and natural products a year for activity against a panel of 60 tumor cell lines in vitro. The result is an information-rich database of patterns that f
Autor:
Elaine S. Marshall, Kenneth D. Paull, Bruce C. Baguley, John H. L. Matthews, Graeme J. Finlay
Publikováno v:
Cancer Chemotherapy and Pharmacology. 31:401-406
The successful treatment of cancer requires the identification of new drugs with novel actions. N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide dihydrochloride (DACA) is a topoisomerase II-targeted antitumour drug with curative activity against muri